- Funding combines equity investment and convertible loan - Focus on best-in-class, clinical-stage peanut allergen neutralizing antibody - Further potential for developing Mabylon’s discovery and pre-clinical pipeline programs - Dr. Thomas Hecht has joined Board of Directors
August 13, 2025
· 1 min read